Abstract:Abstract: The tumor suppressor protein p53, a transcription factor playing a key role in cancer prevention, interacts with DNA as its primary means of determining cell fate in the event of DNA damage. When it becomes mutated, it opens damaged cells to the possibility of reproducing unchecked, which can lead to formation of cancerous tumors. Despite its critical role, therapies at the molecular level to restore p53 native function remain elusive, due to its complex nature. Nevertheless, considerable information has been amassed, and new means of investigating the problem have become available. Objectives: We consider structural, biophysical, and bioinformatic insights and their implications for the role of direct and indirect readout and how they contribute to binding site recognition, particularly those of low consensus. We then pivot to consider advances in computational approaches to drug discovery. Materials and methods: We have conducted a review of recent literature pertinent to the p53 protein. Results: Considerable literature corroborates the idea that p53 is a complex allosteric protein that discriminates its binding sites not only via consensus sequence through direct H-bond contacts, but also a complex combination of factors involving the flexibility of the binding site. New computational methods have emerged capable of capturing such information, which can then be utilized as input to machine learning algorithms towards the goal of more intelligent and efficient de novo allosteric drug design. Conclusions: Recent improvements in machine learning coupled with graph theory and sector analysis hold promise for advances to more intelligently design allosteric effectors that may be able to restore native p53-DNA binding activity to mutant proteins. Clinical relevance: The ideas brought to light by this review constitute a significant advance that can be applied to ongoing biophysical studies of drugs for p53, paving the way for the continued development of new methodologies for allosteric drugs. Our discoveries hold promise to provide molecular therapeutics which restore p53 native activity, thereby offering new insights for cancer therapies. Graphical abstract: Structural representation of the p53 DBD (PDBID 1TUP). DNA consensus sequence is shown in gray, and the protein is shown in blue. Red beads indicate hotspot residue mutations, green beads represent DNA interacting residues, and yellow beads represent both.

p53: A tale of complexity and context

Putting p53 in Context

The first 30 years of p53: growing ever more complex

Functional Diversity of P53 in Human and Wild Animals

Context is key: Understanding the regulation, functional control, and activities of the p53 tumour suppressor

p53: 800 million years of evolution and 40 years of discovery

Blinded by the Light: The Growing Complexity of p53

p53: The Multifaceted Roles of Covalent Modifications in Cancer

Understanding the complexity of p53 in a new era of tumor suppression

Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy

P53 Gain-of-Function: Tumor Biology and Bioinformatics Come Together

Mutant P53 in the formation and progression of the tumor microenvironment: Friend or foe

TP53: the unluckiest of genes?

At a Crossroads to Cancer: How p53-Induced Cell Fate Decisions Secure Genome Integrity

[Advances on Mutant P53 Research].

Targeting p53 pathways: mechanisms, structures, and advances in therapy

Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting

Navigating the complexity of p53-DNA binding: implications for cancer therapy

P53 and The Immune Response: 40 Years of Exploration—A Plan for the Future

Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy

p53 signaling in cancer progression and therapy